881. Temporality of body mass index, blood tests, comorbidities and medication use as early markers for pancreatic ductal adenocarcinoma (PDAC): a nested case-control study.
作者: Pui San Tan.;Cesar Garriga.;Ashley Clift.;Weiqi Liao.;Martina Patone.;Carol Coupland.;Rachael Bashford-Rogers.;Shivan Sivakumar.;Julia Hippisley-Cox.
来源: Gut. 2023年72卷3期512-521页
Prior studies identified clinical factors associated with increased risk of pancreatic ductal adenocarcinoma (PDAC). However, little is known regarding their time-varying nature, which could inform earlier diagnosis. This study assessed temporality of body mass index (BMI), blood-based markers, comorbidities and medication use with PDAC risk .
882. Double-blinded randomised placebo controlled trial of enterosgel (polymethylsiloxane polyhydrate) for the treatment of IBS with diarrhoea (IBS-D).
作者: Carol Angela Howell.;Anu Kemppinen.;Victoria Allgar.;Matthew Dodd.;Charles H Knowles.;John McLaughlin.;Preeti Pandya.;Peter Whorwell.;Elena Markaryan.;Yan Yiannakou.
来源: Gut. 2022年71卷12期2430-2438页
Irritable bowel syndrome with diarrhoea (IBS-D) is a common and challenging condition that significantly reduces quality of life. Enterosgel (polymethylsiloxane polyhydrate) is an intestinal adsorbent which sequesters harmful molecules and is safe and effective in acute infective diarrhoea. This randomised controlled multicentre trial aimed to investigate its safety and efficacy in patients with IBS-D.
884. Activation of NOTCH signaling via DLL1 is mediated by APE1-redox-dependent NF-κB activation in oesophageal adenocarcinoma.
作者: Lei Chen.;Heng Lu.;Dunfa Peng.;Long Long Cao.;Farah Ballout.;Kannappan Srirmajayam.;Zheng Chen.;Ajaz Bhat.;Timothy C Wang.;Anthony Capobianco.;Jianwen Que.;Oliver Gene McDonald.;Alexander Zaika.;Shutian Zhang.;Wael El-Rifai.
来源: Gut. 2023年72卷3期421-432页
Oesophageal adenocarcinoma (EAC) arises in the setting of Barrett's oesophagus, an intestinal metaplastic precursor lesion that can develop in patients with chronic GERD. Here, we investigated the role of acidic bile salts, the mimicry of reflux, in activation of NOTCH signaling in EAC.
886. Hepatic events associated with sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: a nationwide cohort study.
作者: Sungho Bea.;Han Eol Jeong.;Sohee Park.;Oriana H Y Yu.;Yoosoo Chang.;Juhee Cho.;Dong Hyun Sinn.;Young Min Cho.;Ju-Young Shin.
来源: Gut. 2023年72卷5期1020-1022页 887. Kyoto international consensus report on anatomy, pathophysiology and clinical significance of the gastro-oesophageal junction.
作者: Kentaro Sugano.;Stuart Jon Spechler.;Emad M El-Omar.;Kenneth E L McColl.;Kaiyo Takubo.;Takuji Gotoda.;Mitsuhiro Fujishiro.;Katsunori Iijima.;Haruhiro Inoue.;Takashi Kawai.;Yoshikazu Kinoshita.;Hiroto Miwa.;Ken-Ichi Mukaisho.;Kazunari Murakami.;Yasuyuki Seto.;Hisao Tajiri.;Shobna Bhatia.;Myung-Gyu Choi.;Rebecca C Fitzgerald.;Kwong Ming Fock.;Khean-Lee Goh.;Khek Yu Ho.;Varocha Mahachai.;Maria O'Donovan.;Robert Odze.;Richard Peek.;Massimo Rugge.;Prateek Sharma.;Jose D Sollano.;Michael Vieth.;Justin Wu.;Ming-Shiang Wu.;Duowu Zou.;Michio Kaminishi.;Peter Malfertheiner.
来源: Gut. 2022年71卷8期1488-1514页
An international meeting was organised to develop consensus on (1) the landmarks to define the gastro-oesophageal junction (GOJ), (2) the occurrence and pathophysiological significance of the cardiac gland, (3) the definition of the gastro-oesophageal junctional zone (GOJZ) and (4) the causes of inflammation, metaplasia and neoplasia occurring in the GOJZ.
888. Current therapies and new developments in NASH.
作者: Jean-François Dufour.;Quentin M Anstee.;Elisabetta Bugianesi.;Stephen Harrison.;Rohit Loomba.;Valerie Paradis.;Herbert Tilg.;Vincent Wai-Sun Wong.;Shira Zelber-Sagi.
来源: Gut. 2022年71卷10期2123-34页
Non-alcoholic steatohepatitis is becoming the most important aetiology for advanced liver disease. There has been important progress in the field in recent years and the complexity of the pathophysiology of NASH is better understood. Multiple non-invasive circulating and imaging biomarkers have been tested. The importance of lifestyle has been recognised and several drugs are being tested in clinical trials. This review addresses the challenges that healthcare professionals face in the management of NASH patients.
889. Blockade of interleukin 10 potentiates antitumour immune function in human colorectal cancer liver metastases.
作者: Kevin M Sullivan.;Xiuyun Jiang.;Prajna Guha.;Christopher Lausted.;Jason A Carter.;Cynthia Hsu.;Kevin P Labadie.;Karan Kohli.;Heidi L Kenerson.;Sara K Daniel.;Xiaowei Yan.;Changting Meng.;Arezou Abbasi.;Marina Chan.;Y David Seo.;James O Park.;Ian Nicholas Crispe.;Raymond S Yeung.;Teresa S Kim.;Taranjit S Gujral.;Qiang Tian.;Steven C Katz.;Venu G Pillarisetty.
来源: Gut. 2023年72卷2期325-337页
Programmed cell death protein 1 (PD-1) checkpoint inhibition and adoptive cellular therapy have had limited success in patients with microsatellite stable colorectal cancer liver metastases (CRLM). We sought to evaluate the effect of interleukin 10 (IL-10) blockade on endogenous T cell and chimeric antigen receptor T (CAR-T) cell antitumour function in CRLM slice cultures.
890. Protective and aggressive bacterial subsets and metabolites modify hepatobiliary inflammation and fibrosis in a murine model of PSC.
作者: Muyiwa Awoniyi.;Jeremy Wang.;Billy Ngo.;Vik Meadows.;Jason Tam.;Amba Viswanathan.;Yunjia Lai.;Stephanie Montgomery.;Morgan Farmer.;Martin Kummen.;Louise Thingholm.;Christoph Schramm.;Corinna Bang.;Andre Franke.;Kun Lu.;Huiping Zhou.;Jasmohan S Bajaj.;Phillip B Hylemon.;Jenny Ting.;Yury V Popov.;Johannes Roksund Hov.;Heather L Francis.;Ryan Balfour Sartor.
来源: Gut. 2023年72卷4期671-685页
Conflicting microbiota data exist for primary sclerosing cholangitis (PSC) and experimental models.
891. Escape from cell-cell and cell-matrix adhesion dependence underscores disease progression in gastric cancer organoid models.
作者: Yin Tong.;Priscilla S W Cheng.;Chung Sze Or.;Sarah S K Yue.;Hoi Cheong Siu.;Siu Lun Ho.;Simon Y K Law.;Wai Yin Tsui.;Dessy Chan.;Stephanie Ma.;Siu Po Lee.;Annie S Y Chan.;April S Chan.;Shui Wa Yun.;Ho Sang Hui.;Siu Tsan Yuen.;Suet Yi Leung.;Helen H N Yan.
来源: Gut. 2023年72卷2期242-255页
Cell-cell (CC) and cell-matrix (CM) adhesions are essential for epithelial cell survival, yet dissociation-induced apoptosis is frequently circumvented in malignant cells.
893. Comparison of lumen-apposing metal stents versus double-pigtail plastic stents for infected necrotising pancreatitis.
作者: Lotte Boxhoorn.;Robert C Verdonk.;Marc G Besselink.;Marja Boermeester.;Thomas L Bollen.;Stefan Aw Bouwense.;Vincent C Cappendijk.;Wouter L Curvers.;Cornelis H Dejong.;Sven M van Dijk.;Hendrik M van Dullemen.;Casper Hj van Eijck.;Erwin Jm van Geenen.;Muhammed Hadithi.;Wouter L Hazen.;Pieter Honkoop.;Jeanin E van Hooft.;Maarten Ajm Jacobs.;June Ec Kievits.;Marnix Pm Kop.;Eva Kouw.;Sjoerd D Kuiken.;Michiel Ledeboer.;Vincent B Nieuwenhuijs.;Lars E Perk.;Jan-Werner Poley.;Rutger Quispel.;Rogier Jj de Ridder.;Hjalmar C van Santvoort.;Christina J Sperna Weiland.;Martijn Wj Stommel.;Hester C Timmerhuis.;Ben J Witteman.;Devica S Umans.;Niels G Venneman.;Frank P Vleggaar.;Roy Lj van Wanrooij.;Marco J Bruno.;Paul Fockens.;Rogier P Voermans.; .
来源: Gut. 2023年72卷1期66-72页
Lumen-apposing metal stents (LAMS) are believed to clinically improve endoscopic transluminal drainage of infected necrosis when compared with double-pigtail plastic stents. However, comparative data from prospective studies are very limited.
894. COVID-19 and liver disease.
作者: Jean-François Dufour.;Thomas Marjot.;Chiara Becchetti.;Herbert Tilg.
来源: Gut. 2022年71卷11期2350-2362页
Knowledge on SARS-CoV-2 infection and its resultant COVID-19 in liver diseases has rapidly increased during the pandemic. Hereby, we review COVID-19 liver manifestations and pathophysiological aspects related to SARS-CoV-2 infection in patients without liver disease as well as the impact of COVID-19 in patients with chronic liver disease (CLD), particularly cirrhosis and liver transplantation (LT). SARS-CoV-2 infection has been associated with overt proinflammatory cytokine profile, which probably contributes substantially to the observed early and late liver abnormalities. CLD, particularly decompensated cirrhosis, should be regarded as a risk factor for severe COVID-19 and death. LT was impacted during the pandemic, mainly due to concerns regarding donation and infection in recipients. However, LT did not represent a risk factor per se of worse outcome. Even though scarce, data regarding COVID-19 specific therapy in special populations such as LT recipients seem promising. COVID-19 vaccine-induced immunity seems impaired in CLD and LT recipients, advocating for a revised schedule of vaccine administration in this population.
896. 6α-hydroxylated bile acids mediate TGR5 signalling to improve glucose metabolism upon dietary fiber supplementation in mice.
作者: Kassem Makki.;Harald Brolin.;Natalia Petersen.;Marcus Henricsson.;Dan Ploug Christensen.;Muhammad Tanweer Khan.;Annika Wahlström.;Per-Olof Bergh.;Valentina Tremaroli.;Kristina Schoonjans.;Hanns-Ulrich Marschall.;Fredrik Bäckhed.
来源: Gut. 2023年72卷2期314-324页
Dietary fibres are essential for maintaining microbial diversity and the gut microbiota can modulate host physiology by metabolising the fibres. Here, we investigated whether the soluble dietary fibre oligofructose improves host metabolism by modulating bacterial transformation of secondary bile acids in mice fed western-style diet.
897. Gastric emptying study before gastric peroral endoscopic myotomy (G-POEM): can intragastric meal distribution be a predictor of success?
作者: Francesco Vito Mandarino.;Sabrina Gloria Giulia Testoni.;Alberto Barchi.;Gino Pepe.;Dario Esposito.;Lorella Fanti.;Edi Viale.;Paolo Biamonte.;Francesco Azzolini.;Silvio Danese.
来源: Gut. 2023年72卷5期1019-1020页 899. Artificial intelligence in gastroenterology and hepatology: how to advance clinical practice while ensuring health equity.
作者: Eugenia Uche-Anya.;Adjoa Anyane-Yeboa.;Tyler M Berzin.;Marzyeh Ghassemi.;Folasade P May.
来源: Gut. 2022年71卷9期1909-1915页
Artificial intelligence (AI) and machine learning (ML) systems are increasingly used in medicine to improve clinical decision-making and healthcare delivery. In gastroenterology and hepatology, studies have explored a myriad of opportunities for AI/ML applications which are already making the transition to bedside. Despite these advances, there is a risk that biases and health inequities can be introduced or exacerbated by these technologies. If unrecognised, these technologies could generate or worsen systematic racial, ethnic and sex disparities when deployed on a large scale. There are several mechanisms through which AI/ML could contribute to health inequities in gastroenterology and hepatology, including diagnosis of oesophageal cancer, management of inflammatory bowel disease (IBD), liver transplantation, colorectal cancer screening and many others. This review adapts a framework for ethical AI/ML development and application to gastroenterology and hepatology such that clinical practice is advanced while minimising bias and optimising health equity.
|